Newsletter Signup | Community
IMpassion130 clinical trial: The checkpoint inhibitor Tecentriq improves outcomes of Triple Negative Breast Cancer
Checkpoint PD-1 inhibitors and Sacituzumab Govitecan (IMMU-132) promising treatment for triple negative breast cancer
Iniparib Promising in Metastatic Triple-negative Breast Cancer
Obesity Linked with Triple-Negative Breast Cancer
Triple Negative Breast Cancer Linked with Higher Rate of Distant Metastases.
Novel Precision Medicine Promising in Triple-Negative Breast Cancer.
Drs. From Scripps believe that Targaprimir-96 could be the next TNBC treatment?
Dr. Bhuvaneswari Ramaswamy of the OSU Arthur G. James Cancer Hospital answers frequently asked questions about TNBC
Erbitux May Increase Response Rates in Metastatic Triple-Negative Breast Cancer.
Interesting data published this week show HDC appears to benefit TNBC:
